Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

28266

Sigma-Aldrich

Levofloxacin

98.0-102.0% anhydrous basis (HPLC)

Synonym(s):

Levofloxacin Anhydrous, (−)-Ofloxacin

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H20FN3O4
CAS Number:
100986-85-4
Molecular Weight:
361.37
Beilstein:
7327015
MDL number:
MFCD00865049
UNSPSC Code:
51102829
PubChem Substance ID:
57648297
NACRES:
NA.85

biological source

synthetic

Quality Level

200

Assay

98.0-102.0% anhydrous basis (HPLC)

form

powder or crystals

color

light yellow-white to yellow-white

antibiotic activity spectrum

Gram-negative bacteria
Gram-positive bacteria

Mode of action

enzyme | inhibits

SMILES string

OC(C(C1=O)=CN2C(C1=CC(F)=C3N4CCN(C)CC4)=C3OC[C@@H]2C)=O

InChI

1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1

InChI key

GSDSWSVVBLHKDQ-JTQLQIEISA-N

Gene Information

human ... KCNH1(3756)

Looking for similar products? Visit Product Comparison Guide

Application

Levofloxacin is a broad-spectrum antibiotic used in pharmacokinetic , antibiotic resistance , and resistance prevention studies. Antibiotic against bacterial respiratory tract infections.

Biochem/physiol Actions

Levofloxacin is active against Gram-positive and Gram-negative bacteria. It inhibits DNA gyrase (type II topoisomerase) and topoisomerase IV, thereby inhibiting cell division.

Packaging

10mg, 1g, 10g

Other Notes

Keep container tightly closed in a dry and well-ventilated place. Keep in a dry place.

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Danger

Hazard Statements

H302,H317,H334

Hazard Classifications

Acute Tox. 4 Oral - Resp. Sens. 1A - Skin Sens. 1A

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Miriam Hurst et al.
Drugs, 62(14), 2127-2167 (2002-09-25)
Levofloxacin is the L-form of the fluoroquinolone antibacterial agent, ofloxacin. In in vitro studies, levofloxacin demonstrated a broad range of activity against Gram-positive and -negative organisms and anaerobes. The drug is more active against Gram-positive organisms than ciprofloxacin, but less
George G Zhanel et al.
Drugs, 62(1), 13-59 (2002-01-16)
The new fluoroquinolones (clinafloxacin, gatifloxacin, gemifloxacin, grepafloxacin, levofloxacin, moxifloxacin, sitafloxacin, sparfloxacin and trovafloxacin) offer excellent activity against Gram-negative bacilli and improved Gram-positive activity (e.g. against Streptococcus pneumoniae and Staphylococcus aureus) over ciprofloxacin. Ciprofloxacin still maintains the best in vitro activity
Takeshi Hirano et al.
International journal of pharmaceutics, 351(1-2), 113-118 (2007-11-06)
L-Carnitine plays an important role in lipid metabolism by facilitating the transport of long-chain fatty acids across the mitochondrial inner membrane followed by fatty acid beta-oxidation. It is known that members of the OCTN family play an important role in
M H Gotfried et al.
Chest, 119(4), 1114-1122 (2001-04-11)
To determine the steady-state plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM) concentrations of levofloxacin and ciprofloxacin. Multiple-dose, open-label, randomized pharmacokinetic study. Thirty-six healthy, nonsmoking adult subjects were randomized either to oral levofloxacin, 500 or 750 mg once daily
Gregory S Basarab et al.
Scientific reports, 5, 11827-11827 (2015-07-15)
With the diminishing effectiveness of current antibacterial therapies, it is critically important to discover agents that operate by a mechanism that circumvents existing resistance. ETX0914, the first of a new class of antibacterial agent targeted for the treatment of gonorrhea
View All Related Papers

Articles

Inhibition of Nucleic Acid Synthesis by Antibiotics

Quinolones are a key group of antibiotics that interfere with DNA synthesis by inhibiting topoisomerase, most frequently topoisomerase II (DNA gyrase), an enzyme involved in DNA replication.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service